Capstan Medical’s investigational Capstan Compass Robotic System in use during the first U.S. robotic-assisted transcatheter mitral valve replacement (TMVR) procedure, performed by The Christ Hospital Heart & Vascular team under the leadership of Santiago Garcia, MD. Photo courtesy of Capstan Medical.
SANTA CRUZ, Calif., Nov. 16, 2026 | Santa Cruz based Capstan Medical announced today that it has completed its first U.S. robot-assisted transcatheter mitral valve replacement (TMVR), a major step toward bringing its minimally invasive heart valve technology to patients who can't undergo traditional open heart surgery.
The procedure took place November 9 at The Christ Hospital in Cincinnati, Ohio, led by Santiago Garcia, MD, Director of the hospital's Structural Heart Program. It was performed as part of an FDA-authorized early feasibility study using Capstan's investigational Capstan Compass Robotic System.
"I am pleased to report that the procedure was successful, and the patient was discharged home in stable condition," said Dr. Garcia. "This technology has the potential to fundamentally change what is possible for patients who cannot undergo conventional heart surgery, which remains an important unmet clinical need."
Building on a World First in Chile
The U.S. milestone follows Capstan's breakthrough in March 2025, when the company completed the world's first robotic-assisted TMVR procedures in humans. Those two procedures were performed at Hospital Clínico Universidad Católica in Santiago, Chile, by Gonzalo Martinez, MD, Director of the Endovascular Therapy Center at the Pontifical Catholic University of Chile, with Dr. Garcia supporting the cases. It marked the first time a minimally invasive robotic structural heart platform had been used in clinical practice.
Dr. Garcia later presented the results of those first cases at the 2025 Cardiovascular Research Technologies (CRT) meeting in Washington, D.C. His return to lead the first U.S. case brings that early clinical experience full circle.
Why It Matters
Mitral regurgitation happens when the heart's mitral valve doesn't close properly, letting blood flow backward. Many patients are too high-risk for open heart surgery, and existing catheter-based options don't work for everyone.
Capstan's system pairs a flexible, multi-axis catheter with robotic navigation and a novel valve implant. Instead of juggling multiple knobs on a traditional catheter, physicians guide the procedure using a handheld controller, giving them precise control over catheter movement, valve positioning and deployment.
"The Capstan technology lays the foundation for what heart valve intervention should be; simple, reproducible and low-stress," said Maggie Nixon, CEO of Capstan Medical. "We couldn't be more excited for this milestone that makes that future a reality."
A Santa Cruz Success Story
Founded in 2020 and co-founded by CTO Dan Wallace, Capstan has grown into one of Santa Cruz County's standout deep tech companies. Santa Cruz Works has followed the company from its $31.4 million Series B in 2023 to its oversubscribed $110 million Series C in December 2024, and named it a Santa Cruz "Titan" after the Chile procedures. Capstan continues to hire locally, adding to the region's growing medtech and robotics talent base.
Related Articles

